Appendix 2: Tables SNAC-recommended Initial Core Set, September 18, 2009 Table A: Measures that Met the Criteria Thresholds for Validity, Feasibility, and Importance But Were Not Recommended for Inclusion in the Core SetInternal SNAC/AHRQ Control #Measure LabelPrevention and Health PromotionPrenatal/PerinatalPHP-3Smoking Cessation and Prevention: Pregnant womenPHP-26BHRSA MCH Health Status Indicator #01B—% of live singleton births weighing less than 2,500 gmsPHP-26CHRSA MCH Health Status #02A—% of live births weighing less than 1500 gmsPHP-26DHRSA MCH Health status #02B—% of live singleton births weighing less than 1500 gmsPHP-31MCHB National performance measure #8—the rate of birth (per 1,000) for teenagers aged 15-17 yearsPHP-32Proportion of infants 22-29 weeks gestation treated with surfactant who are treated within 2 hours of birthPHP-34Health systems capacity indicator #04-% of women 15-44 with a live birth during the year whose observed to expected prenatal visits are greater than or equal to 80% on the Kotelchuck IndexPHP-36ARate of elective delivery prior to 39 completed weeks gestationImmunizationsPHP-5BTwo-year-old Immunization Measure—Assessing immunizations by timeliness and the ACIP/AAP/CDC schedule versus HEDIS dose counting (OR)General ScreeningPHP-17Newborn Hearing ScreeningPHP-18Vision screening—use MEPS description and performance dataSocial/Behavioral Health ScreeningPHP-33AAdministration of SDBS (Standardized screening tools social and emotional (CMWF/CAHMI))Dental/Oral HealthPHP-42Total eligibles receiving any dental services (EPSDT measure Line 12A)PHP-43AHRSA Oral Health Measures WG Measure—% of children age 12-72 mos with 1 or more fluoride varnish apps documentedManagement of Acute ConditionsAcute Upper Respiratory Tract IllnessAC-1Upper respiratory infection—appropriate treatmentAcute Otitis ExternaAC-11Acute Otitis Externa—Topical therapyAC-13Acute Otitis Externa—Systemic antimicrobial therapy-avoidance of inappropriate useOtitis Media with EffusionAC-14OME Diagnostic evaluation—assessment of tympanic membrane mobilityAC-18OME—systemic corticosteroids—avoidance of inappropriate useInpatient CareAC-5Foreign body left after procedure (PDI 3)AC-6Iatrogenic pneumothorax in non-neonates (PDI)AC-20Care transitions—transition record with specified elements received by discharged patients—InpatientAC-23Central line associated bloodstream infection (PDI 12)AC-24Accidental puncture and lacerationAC-25Decubitus ulcerAC-26AHRQ Pediatric Quality Indicator Composite Measure (Patient Safety Composite)ED CareAC-21Care transition—transition record with specified elements reviewed by discharged patients-EDManagement of Chronic ConditionsMental and Behavioral Health/Substance UseADHD CareCC-1Followup care for children prescribed attention-deficit/hyperactivity disorder (ADHD) medication (Initiation Phase; NCQA measure)HIVCC-8AHIV/AIDS Bureau quality performance measure—percentage of clients with AIDS who are prescribed HAARTCC-23HIV AIDS Bureau Measure—% of clients with HIV infection who had two or more CD4 T-cell counts performed in the measurement yearCC-24HRSA HIV/AIDS QPR % of clients with HIV who had two or more medical visits in an HIV setting in the measurement yearAsthmaCC-10Asthma — appropriate medicationsCC-10BUse of Appropriate Medications for People 5-20 years of age with Asthma – Average number of member controller monthsCC-18Annual influenza vaccination (all children and adolescents diagnosed with asthma)CC-20Annual number of asthma patients (>1 year old) with >1 asthma-related hospitalizationDiabetesCC-14Annual lipid profile (adolescents with diabetes >16 years old)CC-16Annual eye examination (adolescents with diabetes >16 years old)CC-17Annual influenza vaccination (all children and adolescents diagnosed with diabetes)End-Stage Renal DiseaseCC-33Pediatric end-stage renal disease—Plan of care for inadequate hemodialysisCC-34Pediatric end-stage renal disease—influenza immunizationDuration of EnrollmentD-2Retrospective duration measureSource: AHRQ, based on SNAC Delphi II scoring and September 17-18, 2009, SNAC meeting.Return to ContentsTable B: Measures that Did Not Meet Criteria Thresholds for Scoring on Validity, Feasibility, and ImportanceControl NumberMeasure LabelPREVENTION AND HEALTH PROMOTIONPrenatal/PerinatalPHP-1AHRSA MCH MPR #18—% of infants born to pregnant women receiving prenatal care beginning in the first trimester (data source—nvss—differs from NCQA; Medicaid/CHIP specific not available from NVSS.PHP-26Percentage of low birth weight (PDI—hospital discharge data)PHP-27Postpartum care visit NCQA measurePHP-30MCHB National performance measure #17—percent of VLBW infants delivered at facilities for high-risk deliveries and neonatesPHP-30AUnder 1500g infant Not Delivered at Appropriate Level of CarePHP-36Elective delivery prior to 39 weeks gestationPHP-40HRSA MCH NPR MEASURE #11—% of mothers who breastfeed their infants at 6 mos of agePHP-41HRSA MCH NPR #15—% of women who smoke in the last 3 months of pregnancyImmunizationsPHP-8Immunization reporting (provider registry)Adolescent Preventive ServicesPHP-11Adolescent Well-Care Visits (NCQA)PHP-15Adolescent receipt of the following seven components of care during the measurement year: BMI percentile, assessment/counseling/education on nutrition, physical activity, risk behaviors associated with sexual health/activity/preventive actions, depression screeningPHP-16Smoking Cessation and Prevention: adolescent tobacco usersGeneral ScreeningPHP-19Weight Assessment and Counseling for Nutrition and Physical Activity for children and adolescentsPHP-19BNutrition counseling—NCQAPHP 19CPhysical Activity Counseling (NQCA)PHP-29Lead screening rate (NCQA—1st year measure—see confidential data); note USPSTF recommendationPHP-29ALead screening 2nd year—% of members who turned age 2 during the reporting period and received a lead test (data from MaineCare claims and the Maine CDC)PHP-29BLead screening 1st year—% of members who turned age 1 during the reporting period and received a lead test (data from MaineCare Claims and Maine CDC)PHP-29CHRSA Lead screening in children by 2 years of age (data source differs from NCQA)PHP-39EPSDT—Percentage of members 0-20 years old who had one or more EPSDT procedure(s) during the reporting periodSocial/Behavioral Health ScreeningPHP-37Percent of members under age 21 with a WCC visit by any provider during the measurement period who had a BH screen.Dental/Oral HealthPHP-22AHRSA oral health measure—the percentage of patients who had at least one dental visit during the measurement year (differs from NCQA—data source is CHCs; broader age range)PHP-35HRSA oral health measure — percentage of all dental patients with a comprehensive or periodic recall oral exam within a 12 month periodMANAGEMENT OF ACUTE CONDITIONSAcute Otitis ExternaAC-12Acute Otitis Externa—Pain AssessmentOtitis Media with EffusionAC-15Otitis Media with Effusion—Hearing testingDentalAC-8HRSA oral health measure—percentage of all dental patients for whom the Phase I treatment plan is completed within a 12-month periodAC-9HRSA oral health performance measure—percentage of all dental patients with a comprehensive or periodic recall oral exam, for whom the Phase I treatment plan is documentedInpatient CareAC-7PICU pain assessment on admissionAC-19Care transitions—reconciled medication list received by discharged patientsAC-22Care transitions—timely transmission of transition record (from input)ED CareAC-10ER Utilization - Average number of emergency room visits per member per reporting periodAC-21Care transition—transition record with specified elements received by discharged patients-EDMANAGEMENT OF CHRONIC CONDITIONSMental and Behavioral Health/Substance UseADHD CareCC-6Diagnosis of ADHD in primary care for school age children and adolescents (using DSM)Depression CareCC-27Child and adolescent Major Depressive Disorder (MDD)—interview of adolescent or childCC-28Child and adolescent Major Depressive Disorder(MDD)—diagnostic evaluationCC-30Child and adolescent Major Depressive Disorder (MDD)—psychotherapyCC-32Child and adolescent Major Depressive Disorder (MDD)—follow-up careOther Mental Health/Behavioral CareCC-4Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (ages 3-17 and 18+)CC-35Medication adherence as measured by maximal gaps in days during a calendar year for ADHD and anti-psychotics medication in childrenChildren with Special Health Care NeedsCC-37CSHCN number of missed school days due to illness or injuryHIVCC-8Highly active anti-retroviral treatmentAsthmaCC-25Percentage of patients for whom there is documentation that a written asthma management plan was provided to the patient or the patient's caregiver OR at minimum instructions on under what conditions the patient's doctor should be contacted or the patient should go to the emergency room.Chronic Disease Identified through Newborn ScreeningCC-12Timely follow-up of positive newborn screensDiabetesCC-15Annual urine protein screening (adolescents with diabetes > 16 years-old)CC-21Hemoglobin A1c test for pediatric patientsFAMILY EXPERIENCES WITH CAREOther Family/Patient Experiences of Care MeasuresFEC-2Helpfulness of counseling (adolescent reported)FEC-3Communication and experience of care (adolescent reported)FEC-4Dental CAHPS® (overall ratings of dentist, dental plan, dental care, office staff)MOST INTEGRATED HEALTHCARE SYSTEMSMIH-2Medical home measure using subset of HEDIS CAHPS® MEDICAID 4.0 survey itemsAVAILABILITY OF SERVICESAV-1Unduplicated members served per providerUse of ServicesUS-1Utilization of ambulatory servicesUS-2Outpatient drug utilization—per member per year average number of prescriptionsUS-3Utilization of inpatient careAccess to ServicesHEALTH STATUSHS-2PROMIS Pediatric item Banks: physical function, emotional distress, social role relationship, fatigue, pain, and asthmaDURATION OF ENROLLMENTD-1Prospective duration measureKey:V = ValidityF = FeasibilityI = ImportanceIQR = Inter-Quartile RangeN = Number of Subcommittee members rating measure Current as of January 2010 Internet Citation: Appendix 2: Tables: SNAC-recommended Initial Core Set, September 18, 2009. January 2010. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/policymakers/chipra/coreset/coresetap2.html